Cutaneous Rosai-Dorfman Disease
Authors:
- Yun-Yi KongYKYun-Yi Kong
- Jin-Cheng KongJKJin-Cheng Kong
- Da-Ren ShiDSDa-Ren Shi
- Hong-Fen LuHLHong-Fen Lu
- Xiong-Zeng ZhuXZXiong-Zeng Zhu
- Jian WangJWJian Wang
- Zhong-Wei ChenZCZhong-Wei Chen
- 1 March 2007
- journal article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 31 (3) , 341-350
Abstract
Cutaneous Rosai-Dorfman disease (CRDD) is a rare proliferative disorder of histiocytes with unknown etiology, broadly different from systemic Rosai-Dorfman disease. We present the largest series of CRDD, describing the clinical manifestation, histopathology, immunohistochemistry, and follow-up course of 25 cases in China. Clinically, 39 skin lesions in 25 patients were divided into 3 main types: papulonodular type (79.5%), indurated plaque type (12.8%), and tumor type (7.7%). Extremities were the most frequently involved, followed by trunk and face. None of the patients was found to have visceral organ involvement or lymphadenopathy. Microscopically, CRDD was characterized by scattering, clusters or sheets of large polygonal histiocytes intermingled with a florid, mixed inflammatory infiltrate. The most important feature was emperipolesis, which can be highlighted by S-100 protein stain. Patch and bandlike infiltrate of numerous mature plasma cells around glands and vessels was a constant finding in all lesions. Neutrophils existed in all cases to a variable degree with 2 cases forming microabscess. Four cases were remarkable for fibrosis, and xanthomatous change was observed in 2 cases. Coexistence of localized Langerhans cell histiocytosis and CRDD was interestingly found in case 7, which was evidenced by CD1a stain. Clinical follow-up in 22 patients, ranging from 2 to 55 months, indicated that surgical excision was the exclusive effective treatment for CRDD. Partial or complete spontaneous remission was achieved in 7 patients within 6 to 55 months. Owing to its favorable outcome, CRDD should be differentiated from a variety of benign and malignant lesions. Recognition of its wide clinical spectrum and histologic features combined with S-100 protein stain can help to establish the correct diagnosis.Keywords
This publication has 30 references indexed in Scilit:
- Cutaneous Rosai-Dorfman disease: clinicopathological profiles, spectrum and evolution of 21 lesions in six patientsBritish Journal of Dermatology, 2005
- Clinical and histopathologic spectrum of cutaneous Rosai-Dorfman disease in TaiwanJournal of the American Academy of Dermatology, 2004
- Cutaneous Rosai-Dorfman disease: remission with thalidomide treatmentBritish Journal of Dermatology, 2003
- Extranodal Rosai‐ n disease with cutaneous, ophthalmic and laryngeal involvement: report of a case treated with isotretinoinInternational Journal of Dermatology, 2002
- Coexistence of localized Langerhans cell histiocytosis and cutaneous Rosai-Dorfman diseaseBritish Journal of Dermatology, 2002
- Cutaneous Destombes–Rosai–Dorfman disease: absence of detection of HHV‐6 and HHV‐8 in skinJournal of Cutaneous Pathology, 2002
- Sinus Histiocytosis (Rosai-Dorfman Disease) Clinically Limited to the SkinActa Dermato-Venereologica, 1999
- Purely cutaneous Rosai-Dorfman diseaseBritish Journal of Dermatology, 1996
- Cutaneous Rosai‐Dorfman disease presenting as a suspicious breast massJournal of Cutaneous Pathology, 1994
- Sinus histiocytosis (Rosai‐Dorfman disease) clinically limited to the skinJournal of Cutaneous Pathology, 1993